How to Read and Interpret HLA-DR Test Results

HLA-DR test results report which versions of a specific immune-system gene you carry, and understanding them starts with learning a compact naming system. The results typically appear as alphanumeric codes like DRB1*04:01 or DRB1*15:01, where each segment conveys information about the gene, its broad group, and the precise protein variant. But context matters enormously: the same HLA-DR result means very different things depending on whether you are being evaluated for organ transplantation, screened for autoimmune disease risk, or monitored for immune function in an intensive care unit. Knowing how to read the notation is the first step; knowing what it implies for your situation is where interpretation begins.

Decoding the Naming Convention

HLA stands for human leukocyte antigen, and DR is one of several class II molecules in this system. A standardized nomenclature has been overseen by an international committee since 1968, and it has evolved from broad serological categories to precise DNA-based designations.¹ When you see a result like HLA-DRB1*04:01:01, here is what each piece means:

• DRB1: The specific gene being typed. DRB1 is the main HLA-DR gene, but related genes called DRB3, DRB4, and DRB5 also exist and sometimes appear on reports.
• The asterisk (*): A separator indicating that the typing was done at the DNA level rather than the older serological level.
• First field (e.g., 04): The allele group, roughly corresponding to the older serological types. This tells you the broad family your allele belongs to.
• Second field (e.g., 01): The specific protein variant within that group. Two alleles that share the first field but differ at the second field produce slightly different proteins.
• Third and fourth fields: These appear on high-resolution reports and capture DNA-level differences that do not change the protein (third field) or that fall outside the coding region (fourth field). Most clinical decisions rely on the first two fields.

Older reports sometimes use serological shorthand like “DR4” or “DR15” without an asterisk, which maps to the first-field allele group. If your report says DR4, that is equivalent to saying you carry an allele in the DRB1*04 group, but it does not tell you which specific variant within that group you have. The distinction matters in transplantation, where two people who are both “DR4” could still be mismatched at the protein level.

Why Resolution Level Matters

Not all HLA-DR tests provide the same level of detail, and the method used determines how much ambiguity remains. Older probe-based methods almost always produce ambiguous results, meaning the lab cannot distinguish between two or more possible allele combinations. Newer sequencing approaches resolve these ambiguities and deliver unambiguous three-field assignments.² If your report lists allele codes separated by a slash (for example, DRB1*04:01/04:92), that slash indicates the lab could not determine which of those two alleles you actually carry. A high-resolution report without slashes gives you a definitive answer.

In transplant settings, ambiguity can be a real problem. A donor and recipient who appear matched at low resolution could turn out to be mismatched when typed more precisely. If you are told you need “high-resolution typing,” that usually means the transplant team wants second-field (or better) clarity to avoid hidden mismatches.

You Carry Two Alleles, Not One

Because you inherit one copy of chromosome 6 from each parent, your report will list two HLA-DRB1 alleles. You might see something like DRB1*03:01, DRB1*07:01. If both alleles happen to be the same, the report might say DRB1*11:04, DRB1*11:04, meaning you are homozygous at that locus. Being heterozygous (carrying two different alleles) is the norm and is generally considered advantageous for immune function, since it broadens the range of foreign proteins your immune system can recognize.

The HLA-DR and HLA-DQ genes sit close together on chromosome 6 and are usually inherited as a unit, called a haplotype. Recombination between DR and DQ within a single family is extremely rare, with the first documented case reported in the late 1990s.³ This tight linkage means that certain DR alleles almost always travel with certain DQ alleles. Your lab report may list both, and the combination can matter for disease risk assessment. Databases of these common pairings exist and are used to estimate how many potential donors would need to be screened to find a full match for a given patient.⁴

The Secondary DR Genes on Your Report

Some reports include results for DRB3, DRB4, or DRB5 alongside the main DRB1 result. These are secondary genes that are present on some chromosomes but not others, depending on which DRB1 allele you carry. For instance, people with DRB1*04 alleles typically also carry the DRB4 gene, while those with DRB1*15 or DRB1*16 typically carry DRB5. Not everyone has the same number of these secondary genes, and the frequency of DRB4, for example, varies across continental populations. Studies using whole-genome sequencing data from diverse populations have shown that the frequency of DRB4 in African populations is significantly lower than in other groups. Accurate typing and copy-number determination for these secondary genes is now possible with newer sequencing methods, though it was technically challenging with older approaches.

Most of the time, the clinical weight falls on DRB1. But the secondary genes do encode functional molecules that can be targets for the immune system during transplant rejection, so transplant programs increasingly type for them as well.

HLA-DR in Organ Transplantation

If you are reading HLA-DR results in a transplant context, the key question is how well the donor and recipient match at this locus. Mismatches are counted as 0, 1, or 2, reflecting how many of the donor’s two DRB1 alleles differ from the recipient’s. HLA-DR mismatches carry more immunological weight than mismatches at some other HLA loci. Studies have found that class II mismatches (which include DR) trigger a more robust and diverse immune response capable of driving both cellular and antibody-mediated rejection.⁵

A UK registry analysis of kidney transplant outcomes found that a single HLA-DR mismatch was significantly associated with graft failure, while mismatches at the A, B, and DQ loci were not. Ten-year graft survival was about 13% lower with one DR mismatch and roughly 17% lower with two DR mismatches compared to zero.⁶ So if your transplant report shows “0 DR mismatches,” that is the best-case scenario at this locus. One or two mismatches does not mean the transplant cannot proceed, but the team may adjust immunosuppression or weigh other factors more carefully.

For stem cell transplants, the stakes are similarly high. Mismatching at any of the major HLA loci, including DRB1, can cause graft rejection or graft-versus-host disease.⁷ The presence of multiple mismatches across loci is especially harmful, with one large study reporting that patients with multiple mismatches had nearly twice the risk of dying and about two and a half times the risk of severe graft-versus-host disease compared to well-matched pairs.⁸

Understanding Antibody Results Alongside HLA-DR Typing

Transplant workups often include antibody screening in addition to HLA typing. The question being asked is whether the recipient has already formed antibodies against specific donor HLA molecules, including HLA-DR. These donor-specific antibodies (DSA) develop from prior exposures like previous transplants, blood transfusions, or pregnancies. Modern single-antigen bead assays detect DSA with high sensitivity and report results as a mean fluorescence intensity (MFI) value for each HLA antigen.⁹

If your report shows a positive DSA against a donor’s HLA-DR antigen with a high MFI value, that indicates your immune system is primed to attack that specific molecule. The higher the MFI, the stronger the antibody response, though exact cutoff thresholds vary between transplant centers. Pre-existing donor-specific HLA antibodies detected this way have been shown to predict worse transplant outcomes.¹⁰ This does not automatically rule out transplantation, but the team may pursue desensitization protocols or select a different donor.

HLA-DR Alleles and Autoimmune Disease Risk

Outside transplantation, HLA-DR results are sometimes ordered to assess genetic predisposition to autoimmune conditions. The associations between specific alleles and diseases are among the strongest genetic risk factors known in medicine, though carrying a risk allele does not guarantee you will develop the condition.

Type 1 diabetes has one of the best-characterized HLA-DR associations. The combination of a DR3-carrying haplotype and a DR4-carrying haplotype in the same person (the DR3/DR4 heterozygote) confers a substantially higher risk than carrying two copies of either one alone. One large consortium analysis found the DR3/DR4 combination carried an odds ratio of about 16.6, compared to roughly 6.3 for DR3/DR3 and about 5.7 for DR4/DR4.¹¹ The linked DQ alleles appear to contribute significantly to this risk as well, with certain combinations of DQ molecules encoded across the two haplotypes creating a particularly potent risk profile.¹²

For rheumatoid arthritis, a group of related DRB1 alleles sharing a common amino acid sequence (sometimes labeled the “shared epitope”) has long been considered a risk factor. Research has refined this picture: these alleles appear to primarily drive the development of specific antibodies rather than independently causing the disease itself.¹³ If your report flags shared-epitope alleles and you have joint symptoms, your doctor may order additional antibody tests to get a clearer picture.

Multiple sclerosis is consistently associated with the DRB1*15:01 allele across nearly all populations studied.¹⁴ Beyond conferring risk for developing MS, carrying this allele has been linked to faster disability progression, greater brain and spinal cord tissue loss, and more inflammatory lesions on MRI over time.¹⁵

Systemic lupus erythematosus (SLE) shows associations with both DR2 and DR3 haplotypes. In one study of Black patients with SLE, DR3 appeared in about 62% of patients compared to 20% of controls, and DR2 in 41% versus 18%. The combined presence of either or both alleles accounted for 84% of patients and carried a relative risk of about 9.¹⁶ Family-based studies have confirmed that specific combinations of DR2 and DR3 haplotypes contribute graded levels of risk for both disease susceptibility and autoantibody production.¹⁷

Monocyte HLA-DR Expression Is a Different Test Entirely

If you encounter a result labeled “mHLA-DR” or “monocyte HLA-DR expression,” this is not a genetic typing result. It measures how much HLA-DR protein is displayed on the surface of your monocytes (a type of white blood cell) at a given moment, and it is used as a biomarker of immune function, particularly in critically ill patients. Decreased HLA-DR expression on monocytes is a reliable indicator of immunosuppression and correlates with increased risk of secondary infections and death in sepsis patients.¹⁸

This measurement is reported in units like antibodies bound per cell (AB/c) or as a percentage of monocytes expressing HLA-DR, depending on the laboratory method. Low values suggest the immune system is in a suppressed state, which in an ICU setting could prompt clinicians to consider immune-stimulating therapies. A 20-year cohort study of over a thousand septic shock cases has reinforced mHLA-DR as the most reliable and actionable biomarker of sepsis-induced immunosuppression currently available.¹⁹ If you or a family member are seeing this result in an ICU context, it reflects how the immune system is functioning right now rather than what genes you carry.

HLA-DR and Drug Reactions

An emerging use of HLA typing involves predicting susceptibility to certain drug-induced adverse reactions. While HLA-B alleles get the most attention in pharmacogenomics, HLA-DR alleles are implicated too. The haplotype DRB1*15:01-DQB1*06:02 has been linked to liver injury caused by the common antibiotic combination amoxicillin-clavulanate.²⁰ The cancer drug lapatinib provides a particularly well-validated example: carriers of DRB1*07:01 had about a 7.7% risk of significant liver enzyme elevations, compared to just 0.5% in non-carriers.²¹ Pre-treatment HLA typing in these situations lets clinicians weigh the risk before starting therapy.

These pharmacogenomic associations are still being catalogued, and many are not yet part of routine clinical practice. But if your doctor orders HLA typing before starting a specific medication, the result is being used to gauge whether your genetic profile places you at elevated risk for a rare but serious side effect.

Why Your Ethnic Background Affects What Your Results Mean

HLA-DR allele frequencies differ substantially across populations, and this has practical implications for interpretation. A study of five major US ethnic groups found that the distribution of DRB1*13 sub-alleles, for instance, differed significantly among Caucasians, African Americans, Asian/Pacific Islanders, Hispanics, and Native Americans.²² Similarly, a South African study found that the most common DRB1 allele group in people of African descent was DRB1*03, while in those of European descent it was DRB1*15, and in mixed-ancestry individuals it was DRB1*13.²³

This variation matters in two ways. First, for transplantation, a patient from an underrepresented ethnic background may carry alleles that are rare in the donor registry, making it harder to find a well-matched donor. Second, disease-risk associations discovered in one population do not always carry the same weight in another. The DRB1*15:01 link to multiple sclerosis holds up across many populations, but the magnitude of risk and the frequency of the allele itself can vary. When interpreting your results, the population context in which the risk was measured is part of the picture.

These population differences are largely shaped by demographic history: migrations, population bottlenecks, and subsequent expansions explain a large share of how HLA variation is distributed globally.²⁴ Natural selection also plays a role, since the diversity of pathogens in a region drives selection for alleles that can present a broader range of foreign proteins to the immune system. Research has shown that even closely related DRB1 alleles, differing by only a few amino acids, can vary dramatically in how many different pathogen-derived fragments they can bind.²⁵ Alleles in the DRB1*13 group, for example, showed up to 57-fold variation in binding breadth despite sharing over 98% of their amino acid sequence. This is part of why the second and third fields of the allele name can carry so much clinical significance even when the first field is identical.

Common Misunderstandings When Reading HLA-DR Reports

One frequent source of confusion is equating “carrying a risk allele” with “having a disease.” HLA-DR alleles associated with autoimmune conditions increase susceptibility, but plenty of people with these alleles never develop the condition. If your report was ordered as part of a diagnostic workup for an autoimmune disease, the HLA result is one piece of evidence alongside clinical symptoms, antibody tests, and imaging. It is not diagnostic on its own.

Another common mistake is assuming that a “mismatch” in the transplant context means the transplant cannot happen. Transplants routinely proceed with one or even two DR mismatches, especially when other factors (donor age, organ quality, time on the waiting list) favor moving forward. The mismatch information helps calibrate the immunosuppressive regimen and set expectations for long-term monitoring, not issue a binary yes-or-no verdict.

Finally, people sometimes confuse HLA-DR genotyping (which genes you carry, fixed for life) with monocyte HLA-DR expression (how much protein is on your cells right now, which fluctuates with illness). A genotyping result never changes between tests. An mHLA-DR expression result can change hour to hour in a critically ill patient. If you see two HLA-DR results that look completely different, check whether one is a genotype and the other is an expression measurement, because they are answering fundamentally different questions.